GlassScriptPhysician profile
Ariel Chavis
NPI 1417661364
$595.05
in general payments reported to CMS, 2019-2025
16 companies · $15.74 in 2025
The $15.74 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $579 · 2025: $15.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $595.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $137.32 | 2024 | Xcopri |
| Lundbeck LLC | $59.20 | 2024 | Vyepti |
| Emd Serono, INC. | $43.85 | 2024 | |
| Biogen, INC. | $38.61 | 2024 | Vumerity |
| Pfizer INC. | $37.20 | 2024 | |
| Jazz Pharmaceuticals INC. | $34.55 | 2024-2025 | |
| Abbvie INC. | $32.96 | 2024 | |
| Lilly USA, LLC | $32.82 | 2024 | Kisunla |
| Amneal Pharmaceuticals LLC | $30.25 | 2024 | Crexont |
| Takeda Pharmaceuticals U.S.A., INC. | $28.33 | 2024 | Takhzyro |
| Genentech USA, INC. | $23.87 | 2024 | Ocrevus |
| Neurocrine Biosciences, INC. | $23.16 | 2024 | Ingrezza |
| Alexion Pharmaceuticals, INC. | $22.40 | 2024 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $20.52 | 2024 | Acthar |
| Metacel Pharmaceuticals LLC | $15.45 | 2024 | Ozobax |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $14.56 | 2024 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariel Chavis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.